Gilead’s Livdelzi Achieves Key Phase 3 Success in Liver Disease Trial, Strengthening Treatment Outlook for PBC Patients
3 June 2026

Gilead’s Livdelzi Achieves Key Phase 3 Success in Liver Disease Trial, Strengthening Treatment Outlook for PBC Patients

Gilead Sciences has announced positive results from its Phase 3 IDEAL trial evaluating Livdelzi (seladelpar)in adults with primary biliary cholangitis (PBC), a rare chronic autoimmune liver disease. The study met its primary endpoint, demonstrating statistically significant improvement in a composite measure of alkaline phosphatase (ALP) normalization compared with placebo.

3 June 2026
Serum Institute to Manufacture Oxford’s Experimental Ebola Vaccine After CEPI Commits 8.6 Million USD Funding

The Serum Institute of India (SII) has joined hands with the University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo strain of Ebola virus, a deadly pathogen currently driving outbreaks in the Democratic Republic of Congo (DRC) and Uganda. CEPI has committed up to 8.6 million USD to support the vaccine's advancement toward clinical testing.

3 June 2026
Study Finds Antibiotics for Routine Sore Throats Offer Little Protection Against Severe Strep Infections

Prescribing antibiotics for common sore throats may have only a minimal impact on preventing serious streptococcal infections, according to new research from the University of Gothenburg. The findings challenge a widely debated rationale for antibiotic use and highlight the importance of recognizing early signs of severe illness instead.

3 June 2026
New Technology Reveals Why Antibody Cancer Drugs Often Fail in Solid Tumors
Researchers at Vanderbilt University Medical Center have developed a novel technology that may help explain why many antibody-based cancer therapies show limited effectiveness in patients with solid tumors such as head and neck cancer and pancreatic cancer. The breakthrough could pave the way for more precise and effective cancer treatments in the future.
2 June 2026
Recruitment for Pharmacists (18 posts) In Central Industrial Security Force
Degree in Pharmacy granted by an institution recognized by the Central or State Government, & Should be registered as a PHARMACIST under the Pharmacy Act, 1948. CISF
2 June 2026
DRDO Scientist Recruitment Open | Formulation design and development
At least First class Masters Degree in M.Pharmacy (Pharmacology) or M.Sc . (Pharmacology) from a recognized University or equivalent. RAC, DRDO
2 June 2026
Applications are invited for the post of Pharmacist in District Health Society
D.Pharm / Integrated Pharmacy Course (for Certificates issued government of Tamil Nadu only) 
2 June 2026
Scientific positions at Forensic Science Laboratory | 148 Junior Scientific Assistant at DSSSB - Departments of Government of NCT of Delhi
opportunities with DSSSB Recruitment 2026. Apply for Junior Scientific Assistant posts in Biology, Chemistry, Documents, HRD/QC. Check eligibility, vacancies, age limit, salary and application dates. Masters degree in Zoology or Botany or Microbiology or Anthropology or Biology or Human Biology or Life Science or Biochemistry or Microbiology or Genetics or Biotechnology or Molecular Biology
2 June 2026
Career for Pharmacy and Biotechnology candidates at NABI
BVSc/ B Tech / MSc / B Pharma in Biotechnology/ Food and Nutritional Sciences/ Technology/ Instrumentation/ Agricultural Biotechnology OR equivalent qualification with 02 years of relevant experience. National Agri-Food and Biomanufacturing Institute 
2 June 2026
Interview for Pharma Assistant Professor at Dibrugarh University
First Class M.Pharm in Pharmacognosy with Basic Degree in Pharmacy (B. Pharm). Experience of teaching/research work is desirable. Dibrugarh University